Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective [18F]AlF-FAPI-74 PET/CT imaging in suspected endometriosis
2026-525272-25-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [18F]-FAPI-74 in endometriosis (2 cohorts), sponsored by UZ Leuven. Planned start Sep 2026; status: authorised.
02
Drugs
[18F]-FAPI-74
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2026-525272-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525272-25-00.